Lv41
420 积分 2024-09-22 加入
The Discovery and Development of Ruxolitinib for the Treatment of Myelofibrosis
7天前
已关闭
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
8天前
已完结
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
30天前
已完结
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
1个月前
已完结
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
1个月前
已完结
Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice
1个月前
已完结
The unexpected role of GIP in transforming obesity treatment
1个月前
已完结
Glucagon, from past to present: a century of intensive research and controversies
1个月前
已完结
Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor
1个月前
已完结
Perspective of CADD and AIDD in medicinal chemistry
1个月前
已关闭
皖公网安备34019202002308
